Company intelligence / Profile preview

Meacor

Irvine, California, USAmeacor.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Meacor is developing the Cryocinch system, a novel minimally invasive transcatheter heart valve repair technology using on-demand cryoadhesion to anchor devices for mitral and tricuspid regurgitation. The approach aims to replicate surgical annuloplasty with fewer complications and shorter recovery times. As of mid 2024, the device is investigational and not yet approved for commercial use; no published clinical trial results are available.

Therapeutic areas: Cardiovascular
Modalities: Device (Transcatheter heart valve repair system)Cryo-adhesion-based anchoring system
Industry: Therapeutic Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of June 2024; senior advisors include leading cardiologists from academic centers.

Beyond the preview

Go deeper on Meacor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meacor.

Explore the full profile